Form 4/A for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-03-30 00:00:00 ET · period of report 2022-03-23 · accession 0001567619-22-007727 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2022-03-30 | 2022-03-23 | ARQT | Turney Patricia A. | SVP, Ops | M - OptEx | $6.52 | +25.3K | 56.4K | +81% | +$165.1K |
| DA | 2022-03-30 | 2022-03-23 | ARQT | Turney Patricia A. | SVP, Ops | M - OptEx | $0.00 | -25.3K | 134.6K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-23 | M | A | 25,328 | $6.52 | 56,441 | D | — | — | (F1) Includes 24,925 restricted stock units. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-23 | M | D | 25,328 | $0.00 | 134,615 | D | $6.52 · — to 2029-11-20 | 25,328 Common Stock | (F2) The option vests as to 1/4 of the total shares on November 14, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on November 14, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. |